Reuters logo
2 months ago
BRIEF-Ablynx initiates study of caplacizumab in healthy Japanese subjects
June 26, 2017 / 5:10 AM / 2 months ago

BRIEF-Ablynx initiates study of caplacizumab in healthy Japanese subjects

June 26 (Reuters) - Ablynx NV:

* ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS

* ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS

* TO COMPARE PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) PROFILES OF CAPLACIZUMAB IN JAPANESE AND CAUCASIAN SUBJECTS

* TO EVALUATE IMMUNOGENICITY OF CAPLACIZUMAB IN JAPANESE SUBJECTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below